Dudediligence.

Invivyd, Inc

IVVDNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$9.3MSep ’24$13.8MDec ’24$11.3MMar ’25$11.8MJun ’25$13.1MSep ’25$17.2MDec ’25$13.7MMar ’26$14.3MJun ’26
Net income, by quarter
−$60.7MSep ’24−$18.4MDec ’24−$16.3MMar ’25−$14.7MJun ’25−$10.5MSep ’25−$11.1MDec ’25−$41.4MMar ’26−$44.4MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenuenone on filenone on file$0.00$25.4M$53.4M
Operating income−$226.9M−$248.0M−$212.8M−$176.9M−$55.6M
Net income−$226.8M−$241.3M−$198.6M−$169.9M−$52.5M
Operating cash flow−$184.7M−$220.0M−$173.2M−$170.5M−$58.1M
Free cash flow−$184.8M−$221.7M−$173.8M−$170.6M−$58.3M
Cash$542.2M$92.1M$200.6M$69.3M$226.7M
Shares outstanding110.8M109.0M110.2M119.8M282.0M